Highly specific inhibitors of ME3 could provide an effective therapy across a number of cancer patients (Dey et al., 2018), and ME3 was proven to be found in pancreatic cancer, which is a gastrointestinal tumor. The gene discussed is ME3; the disease is familial pancreatic carcinoma.